课题基金 / 基金详情

Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines

Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines
使用 HIVIS DNA 和 MVA-CMDR 疫苗针对儿童中的 HIV 储存者
批准号:
10700241
负责人:
Paolo Palma
金额:
$151.9万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-02-01 至 2025-02-28

项目摘要

项目成果

Paolo Palma的其他基金

相似基金

相关文献

中文摘要
翻译
这将是首个针对hiv DNA和MVA-CMDR治疗性疫苗的儿科研究。我们的
英文摘要
This will be the first pediatric study with prime-boost HIVIS DNA and MVA-CMDR therapeutic vaccines. Our goal is to develop therapeutic HIV vaccines to reduce the HIV reservoirs in children and youth with HIV. Our scientific premise is that the prime-boost HIVIS DNA and MVA-CMDR vaccines induce cellular and humeral immune responses important for clearing infected cells. They were selected for children based on ample adult safety data. Early treated children are an ideal population to investigate therapeutic HIV vaccines because of their healthy immunity and small HIV reservoirs. We will explore a novel strategy of giving a licensed vaccine against human papilloma virus that contains toll-like receptor (TLR) 4 agonist adjuvant to boost immune responses to HIVIS DNA. Participants will be children from South Africa. The project was conceptualized under the EPIICAL Consortium and will be conducted in collaboration with the U.S Military HIV Research Program. EPIICAL does not provide any funding for this study but provides a platform for sharing expertise, data and samples from cohorts that will propel the development of therapeutic vaccine strategies for children forward. A maximum of twenty-five participants will be enrolled in this 72-week study. Participants will be 9 to 25 years old, have started HIV medications prior to 6 months of age and are virally suppressed. They will be randomly assigned to HIV vaccines (n=10) vs. HIV vaccines+ TLR4 agonist (n=10) vs. control (no interventions) (n=5). Vaccines will be given at weeks O and 4 for HIVIS DNA, weeks 0, 4 and 24 for TLR4 agonist, and weeks 24 and 36 for MVA-CMDR. We will extensively measure the changes of HIV reservoirs and immune responses post interventions. Aim 1: To quantitate and characterize the HIV reservoirs before and after HIVIS DNA ± TLR4 agonist and MVA-CMDR vaccination Aim 2: To characterize HIV-specific cellular and humeral immune responses before and after vaccination and assess their relationship to the HIV reservoir endpoints. The knowledge generated will contribute to the optimization of therapeutic HIV vaccine strategies and exert sustained influence on HIV cure research for children and youth.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines
Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines
海外基金